Drug intelligence / Profile preview

BCL-KL-002

Development stage: Preclinical
Lead developer: Bioclonal
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

BCL-KL-002 is a preclinical-stage monoclonal antibody being developed by Bioclonal for the treatment of Alzheimer's disease and other neurodegenerative conditions. The drug is part of Bioclonal's KL program, which focuses on targeting specific peptide-based antigens involved in the pathology of neurodegeneration. While the exact molecular target remains undisclosed, the antibody is designed to act as a targeted immunotherapy to address the underlying causes of cognitive decline and neuronal loss.

Beyond the preview

Go deeper on BCL-KL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL-KL-002.

Explore the full profile